Stability or calm before next fight?

This week, the U.S. Supreme Court ruled on that the subsidies offered as part of the Affordable Care Act (ACA) will be available nationwide, regardless of whether they are used to buy health insurance on an exchange established by the federal government or an individual state.

The decision marks the second time the Supreme Court has ruled in support of a major plank of the ACA, the Obama administration’s signature healthcare reform. In 2012, the court ruled that the law’s individual mandate to purchase insurance was constitutional.

This time, the issue revolved around language in the law involving the granting of subsidies to help poor and middle-class individuals purchase insurance coverage. A number of states created their own insurance exchanges, but 34 states are relying on a federal marketplace to facilitate coverage.

Organizations already are saying the decision returns some stability to the ACA and healthcare. Given the contentious nature of everything surrounding the ACA, I wouldn't be surprised if there is yet another attempt to dismantle the law in our future.

Beth Walsh

Clinical Innovation + Technology editor

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.